ESMO 2023

Remarkable efficacies in patients with HER2+ mBC with…

My highlights of ESMO23 in metastatic breast cancer

DATO-DX - where is it going?

Preoperative checkpointinihition in ER+ disease

5 year follow-up

When the history of ADC is written: Redefining…

Lu-PSMA leads forward

Early use of enzalutamide in advanced prostate cancer

Clearing up non-clear cell RCC

The FGFR story in bladder cancer at ESMO23

ALINA - immediate change of practice!

My highlights from ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Perioperativ immunotherapy for all resectable stage…

Amivantamab as a new SoC for EGFR Exon 20…

New and better biomarkers are needed!

Anticipated updates and exciting new data for…

What was the most exciting news at ESMO23?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

Our guidelines are correct

New data on neoadjuvant immunotherapy

Negative EFS results from NeoTrip

MonarchE - trial update

Carry-over effects in monarchE confirmed

Clinically relevant effect of pembro also in PCR

Prognostic score in early HR+/HER2-BC: translational…

My highlights of ESMO23 in early breast cancer

Ribociclib effective in all subtypes

Immunoncology in eBC - triple negative and more?

ER-low corresponds diagnostically to ER-0 breast cancer

Highlights in eBC

Consolidation of data in early HR+ and triple-negative…

Preoperative checkpointinihition in ER+ disease

Metabolomics reveal differential expression of OMEGA 3…

HR+ study with > 20 % PCR

Analysis of tumour microenvironment and…

Neoadjuvant IO - is their new strategy in HR+ breast…

Detailed view of nodal-negative patients

Use of immunotherapy in the perioperative setting of…

5 year follow-up

Nouvelles données sur l'immunothérapie néoadjuvante

Punti salienti in eBC

MonarchE - mise à jour de l'essai

Studio NeoTrip: negativi i risultati

New ADC for metastatic breast cancer?

ADCs in HER2+, HER2low and TNBC - what is the future of…

What was the most exciting news at ESMO23?

Improvement of therapy outcome by app-based patient…

New targets, new linker, new ADCs - much more to learn…

TROP2 expression as a potential mechanism of resistance…

DATO-DX - where is it going?

Benefit for SG even after intensive pretreatment

Dato-DXd - new player in advanced luminal disease

My highlights of ESMO23 in metastatic breast cancer

Even more new generation ADCs in breast cancer?

HER2DX in the PHERgain trial

OP-1250 (Palezestrant) confirms the role of SIRDs after…

Our guidelines are correct

New ADC in HR+ disease

Remarkable efficacies in patients with HER2+ mBC with…

Highlights in mBC

ADC + Immunotherapy - the BEGONIA study paradigm

Robust data from the monarchE

Still on track for success in HER2-low MBC

T-DXd - new standard of care for brain mets?

T-DXd in HER2+ patients with brain metastases

Improved oncological therapy with the smartphone

Patient-centered molecular medicine - a new approach

Abemaciclib remains consistent in 5-year follow-up

Can surgery be spared following primary systemic…

Duvalumab + Dato-DXd effective

OP seems to be dispensable for super responders

TULIP: Trastuzumab duocarmazine without OS benefit

T-DXd also effective for brain metastases

HS20089 - a novel ADC is coming for TNBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

T-DXd - nowy standard postępowania w przerzutach do…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

HER2DX en el estudio PHERgain

Punti salienti in mBC

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

La expresión de TROP2 como potencial mecanismo de…

Lo studio BEGONIA nelle paziento con tumore triplo…

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust…

The optimal timing of RT after radical prostatectomy…

CXCR2 inhibitor in PCa

Combination of radioligand therapy with chemotherapy…

ENZA P:Trial and controversies

When immunotherapy is probably not the best choice: The…

RADICALS RT: Trial and controversies

Lu-PSMA leads forward

PSMAfore unleashes urooncologic opportunity

IO therapy in metastatic prostate cancer.

Osteoprotection at mHSPC

Precision medicine at mCRCP

Negative data for pembrolizumab in mHSCPC & mCRPC

Brave New World in mCRPC

EMBARK expands ENZA indication to PCa

TITAN: ultra-low PSA = best prognosis

PSMA FORE: Trial and controversies

Immunotherapy in metastatic PCa

Longterm toxicity of adjuvant RT after prostatectomy

STAMPEDE. Bone prediction not for everyone - better…

Embark without fear

EMBARK - Quality of Life

Salvage radiotherapy the new standard

Big data and AI prediction tools

Cuando la inmunoterapia probablemente no es la mejor…

Immunterapi vid prostatacancer

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

CXCR2 hämmare och prostatacancer

FGFR inhibitors and ADC combinations in urothelial…

Part1: New standard of care in first line urothelial…

When the history of ADC is written: Redefining…

FGFR inhibitors: What is the best scenario for this…

Chemo-IO establishes itself in the first-line treatment…

The FGFR story in bladder cancer at ESMO23

Amazing new data in bladder cancer

New SoC in firstline bladder cancer

DAD, DAD-IO

Unique bladder delivery system of gemcitabine herolds…

Reescribiendo la historia de una enfermedad: Nuevo…

Inhibidores de FGFR: Cual es el mejor escenario para…

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Important new treatment option but only for subset of…

Is de-escalating therapy ready for prime-time?

Kidney cancer highlights at ESMO23

Belzutifan in later lines of therapy

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Belzutifan - whats next kidney cancer?

Intermittent therapy also possible with TKIs

Moving patients to the neoadjuvant setting in…

Neoadjuvant chemo-immunotherapy new standards in early…

Adjuvant alectinib in patients with early-stage ALK+…

Scene is set for inductive immunotherapy

Perioperative IO: OS-benefi from KEYNOTE-671

Circulating DNA in AEGEAN trial

Perioperativ immunotherapy for all resectable stage…

ALINA - a new paradigm in operated NSCLC with…

My highlights from ESMO 2023

Substantial improvement in local regional NSCLC

Big improvements in early stage and a subset of…

Gros progrès dans les traitments medicaeux des stades…

Perioperatieve chemo-immunotherapie voor alle patienten…

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

Activating EGFR-mutation - what's coming up?

Rare oncogenic alterations: landmark results on exon 20…

ESMO2023-impact on everyday practice!

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Do ADCs have brain activity?

Amivantamab as a new SoC for EGFR Exon 20…

Big improvements in early stage and a subset of…

MARIPOSA II: Trial and controversies

LIBRETO - a positive study, but was it necessary?

Treatment sequences for EGFR-mutated Patients

New standard of care for metastatic EGFR exon 20…

Does immunotherapy still have a place in EGFR-positive…

Amivantamab upfront? MARIPOSA trial

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

My highlights from ESMO 2023

Amivantamab at progression? MARIPOSA-2 trial

Practice changing results on exon 20 insertion mNSCLC

Substantial improvement in rare alterations

Adagrasib + pembrolizumab in patients with KRASG12C…

TROPION-Lung01: positive development

NRG fusions: a new drugable target?

Changing treatment landscape in EGFR-mutated NSCLC

Brain metastases – options to improve the systemic…

By unanimous decision and still the champion –…

PAPILLON - bringing together therapy for the 1st line

I miei punti salienti di ESMO 2023

Heeft immunotherapie nog een plek in de behandeling van…

Les points forts de l'ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Quelles séquences thérapeutiques pour les patients EGFR…

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Amivantamab upfront? MARIPOSA trial

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Amivantamab at progression? MARIPOSA-2 trial

L’amivantamab, nouveau standard de traitement pour les…

Tarlatamab in SCLC

A new option in relapsed SCLC

Evolution of the revolution - the RUBY trial

Update on gynaecological cancers

New data on sarkomas

Precision oncology in CUP

First data on luveltamab in multiline treatment for…

PCO Therapeutics